Drugs in Dev. Infections and Infectious Diseases
Phase I/ Phase II
India 
Lead Product(s) : AKS-452
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AKS-452 is a CoV-2 protein subunit vaccine based on the Ambifect™ Fc-fusion protein platform. It induces a Th1/Th2 mixed immune response in patients against the Receptor Binding Domain (RBD) of the novel coronavirus spike protein.
Product Name : AKS-452
Product Type : Vaccine
Upfront Cash : Inapplicable
June 24, 2022
Lead Product(s) : AKS-452
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetravalent Chimeric Dengue Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DengiAll, a single-dose live-attenuated tetravalent vaccine induced robust, balanced neutralizing antibody responses against all four Dengue virus serotypes. After single-dose, more than 80% of participants showed Tri-valent response and ~95% showed mult...
Product Name : DengiAll
Product Type : Vaccine
Upfront Cash : Inapplicable
September 30, 2021
Lead Product(s) : Tetravalent Chimeric Dengue Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Umbilical Cord Derived Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Derived from Mesenchymal stem cells obtained from donated umbilical cord tissue, Mesocel is set to treat patients suffering from life-threatening Covid-19 pneumonia and acute respiratory distress.
Product Name : Mesocel
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 15, 2021
Lead Product(s) : Human Umbilical Cord Derived Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : HDT Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India
Details : Gennova Biopharmaceuticals, successfully completed a Phase 1 trial of its COVID-19 RNA vaccine candidate HGCO19 and Indian regulatory authorities have approved the start of pivotal Phase 2/3 trials.
Product Name : HGCO19
Product Type : Vaccine
Upfront Cash : Inapplicable
August 31, 2021
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : HDT Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HGCO19 Vaccine Candidate: Gennova Starts Enrolment for Phase 1/2 Human Clinical Trials
Details : HCCOG19 is an indigenously developed vaccine on a mRNA platform. Gennova has initiated the enrolment of volunteers for Phase 1/2 clinical trials for its mRNA vaccine candidate HGCO19, the Department of Biotechnology.
Product Name : HGCO19
Product Type : Vaccine
Upfront Cash : Inapplicable
April 13, 2021
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : CEPI
Deal Size : $5.0 million
Deal Type : Funding
CEPI Partners with Biological E To Advance Development and Manufacture of Covid-19 Vaccine Candidate
Details : CEPI will initially contribute up to $5m toward the cost of scaling up the process for manufacturing the COVAX, and will explore providing additional funding to Bio E with the goal of potentially enabling the production of 100 million doses in 2021.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
December 29, 2020
Lead Product(s) : COVID-19 Vaccine,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : CEPI
Deal Size : $5.0 million
Deal Type : Funding
Lead Product(s) : ZyCoV-D
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Cadila Seeks Govt Nod to Start Phase-III Clinical Trials of Covid-19 Vaccine ZyCoVD
Details : Zydus Cadila's ZyCoV-D', has been found to be safe and immunogenic in the Phase I/II clinical trials, and the company is seeking regulatory approval to commence Phase-III trials.
Product Name : ZyCoV-D
Product Type : Vaccine
Upfront Cash : Inapplicable
December 24, 2020
Lead Product(s) : ZyCoV-D
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Bayer college of medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
India's Biological E. to Start Vaccine Late-Stage Trials in April
Details : Company said in November it had started early-stage and mid-stage human trials of its vaccine candidate, being developed in collaboration with Baylor College of Medicine in Houston and U.S.-based Dynavax Technologies Corp, and expects results by February...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
December 18, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Bayer college of medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : International Finance Corporation
Deal Size : $30.0 million
Deal Type : Funding
IFC Supports Biological E to Expand Access to Low-Cost Vaccines in Developing Countries
Details : International Finance Corporation has invested $30 million, or about Rs 221 crore, in Indian vaccine maker Biological E to help the latter expand its range of low-priced, generic vaccines for routine immunisation of children and new vaccines including fu...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
December 17, 2020
Lead Product(s) : COVID-19 Vaccine,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : International Finance Corporation
Deal Size : $30.0 million
Deal Type : Funding
Lead Product(s) : COVID-19 Vaccine,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Dynavax Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
Biological E. Limited Starts Phase I/II Clinical Trial of its COVID-19 Vaccine Candidate
Details : BE's Phase I/II clinical trial will evaluate the safety and immunogenicity of the vaccine candidate consisting of the Receptor Binding Domain of the Spike Protein of SARS-CoV-2 at three dose levels adjuvanted with CpG 1018 plus alum, in about 360 healthy...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : COVID-19 Vaccine,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Dynavax Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.
